{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:00Z","timestamp":1792706940804,"version":"4.5.0"},"reference-count":147,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.1248\/bpb.b25-00796","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:11:18Z","timestamp":1774995078000},"page":"601-617","source":"Crossref","is-referenced-by-count":2,"title":["Transporters for Creatine and Related Guanidino Compounds: Their Relevance to Brain Health and Disorders"],"prefix":"10.1248","volume":"49","author":[{"given":"Masanori","family":"Tachikawa","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. <i>J. Cereb. Blood Flow Metab.<\/i>, <b>32<\/b>, 1222\u20131232 (2012).","DOI":"10.1038\/jcbfm.2012.35"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. <i>Physiol. Rev.<\/i>, <b>80<\/b>, 1107\u20131213 (2000).","DOI":"10.1152\/physrev.2000.80.3.1107"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>102<\/b>, 808\u2013813 (2005).","DOI":"10.1073\/pnas.0408962102"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. <i>Eur. J. Neurosci.<\/i>, <b>20<\/b>, 144\u2013160 (2004).","DOI":"10.1111\/j.1460-9568.2004.03478.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tachikawa M, Watanabe M, Fukaya M, Sakai K, Terasaki T, Hosoya KI. Cell-type-specific spatiotemporal expression of creatine biosynthetic enzyme S-adenosylmethionine:guanidinoacetate <i>N<\/i>-methyltransferase in developing mouse brain. <i>Neurochem. Res.<\/i>, <b>43<\/b>, 500\u2013510 (2018).","DOI":"10.1007\/s11064-017-2446-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE. Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. <i>Behav. Brain Res.<\/i>, <b>157<\/b>, 219\u2013234 (2005).","DOI":"10.1016\/j.bbr.2004.07.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Aksenov MY, Aksenova MV, Payne RM, Smith CD, Markesbery WR, Carney JM. The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer\u2019s and Pick\u2019s disease. <i>Exp. Neurol.<\/i>, <b>146<\/b>, 458\u2013465 (1997).","DOI":"10.1006\/exnr.1997.6550"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fernandes-Pires G, Braissant O. Current and potential new treatment strategies for creatine deficiency syndromes. <i>Mol. Genet. Metab.<\/i>, <b>135<\/b>, 15\u201326 (2022).","DOI":"10.1016\/j.ymgme.2021.12.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Schulze A. Creatine deficiency syndromes. <i>Mol. Cell. Biochem.<\/i>, <b>244<\/b>, 143\u2013150 (2003).","DOI":"10.1007\/978-1-4615-0247-0_22"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Almeida LS, Salomons GS, Hogenboom F, Jakobs C, Schoffelmeer AN. Exocytotic release of creatine in rat brain. <i>Synapse<\/i>, <b>60<\/b>, 118\u2013123 (2006).","DOI":"10.1002\/syn.20280"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z, Zhang W, Rao Y. Suggestion of creatine as a new neurotransmitter by approaches ranging from chemical analysis and biochemistry to electrophysiology. <i>eLife<\/i>, <b>12<\/b>, RP89317 (2023).","DOI":"10.7554\/eLife.89317"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Braissant O, Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. <i>J. Inherit. Metab. Dis.<\/i>, <b>31<\/b>, 230\u2013239 (2008).","DOI":"10.1007\/s10545-008-0826-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells. What can be learned from human creatine deficiencies and various experimental models? <i>Amino Acids<\/i>, <b>48<\/b>, 1877\u20131895 (2016).","DOI":"10.1007\/s00726-016-2189-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hiramatsu M. A role for guanidino compounds in the brain. <i>Mol. Cell. Biochem.<\/i>, <b>244<\/b>, 57\u201362 (2003).","DOI":"10.1007\/978-1-4615-0247-0_8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, Jakobs C. X-Linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. <i>Am. J. Hum. Genet.<\/i>, <b>68<\/b>, 1497\u20131500 (2001).","DOI":"10.1086\/320595"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cecil KM, Salomons GS, Ball WS Jr, Wong B, Chuck G, Verhoeven NM, Jakobs C, DeGrauw TJ. Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? <i>Ann. Neurol.<\/i>, <b>49<\/b>, 401\u2013404 (2001).","DOI":"10.1002\/ana.79"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, <i>et al.<\/i> Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. <i>J. Med. Genet.<\/i>, <b>50<\/b>, 463\u2013472 (2013).","DOI":"10.1136\/jmedgenet-2013-101658"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) van de Kamp JM, Mancini GM, Pouwels PJ, Betsalel OT, van Dooren SJ, de Koning I, Steenweg ME, Jakobs C, van der Knaap MS, Salomons GS. Clinical features and X-inactivation in females heterozygous for creatine transporter defect. <i>Clin. Genet.<\/i>, <b>79<\/b>, 264\u2013272 (2011).","DOI":"10.1111\/j.1399-0004.2010.01460.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) van de Kamp JM, Pouwels PJ, Aarsen FK, ten Hoopen LW, Knol DL, de Klerk JB, de Coo IF, Huijmans JG, Jakobs C, van der Knaap MS, Salomons GS, Mancini GM. Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. <i>J. Inherit. Metab. Dis.<\/i>, <b>35<\/b>, 141\u2013149 (2012).","DOI":"10.1007\/s10545-011-9345-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Li J, Xu S. Diagnosis and treatment of X-linked creatine transporter deficiency: case report and literature review. <i>Brain Sci.<\/i>, <b>13<\/b>, 1382 (2023).","DOI":"10.3390\/brainsci13101382"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Osaka H, Takagi A, Tsuyusaki Y, Wada T, Iai M, Yamashita S, Shimbo H, Saitsu H, Salomons GS, Jakobs C, Aida N, Toshihiro S, Kuhara T, Matsumoto N. Contiguous deletion of SLC6A8 and BAP31 in a patient with severe dystonia and sensorineural deafness. <i>Mol. Genet. Metab.<\/i>, <b>106<\/b>, 43\u201347 (2012).","DOI":"10.1016\/j.ymgme.2012.02.018"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kato H, Miyake F, Shimbo H, Ohya M, Sugawara H, Aida N, Anzai R, Takagi M, Okuda M, Takano K, Wada T, Iai M, Yamashita S, Osaka H. Urine screening for patients with developmental disabilities detected a patient with creatine transporter deficiency due to a novel missense mutation in SLC6A8. <i>Brain Dev.<\/i>, <b>36<\/b>, 630\u2013633 (2014).","DOI":"10.1016\/j.braindev.2013.08.004"},{"key":"23","unstructured":"23) Nozaki F, Kumada T, Shibata M, Fujii T, Wada T, Osaka H. A family with creatine transporter deficiency diagnosed with urinary creatine\/creatinine ratio and the family history: the third Japanese familial case. <i>No To Hattatsu<\/i>, <b>47<\/b>, 49\u201352 (2015)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Abe-Hatano C, Iida A, Kosugi S, <i>et al.<\/i> Whole genome sequencing of 45 Japanese patients with intellectual disability. <i>Am. J. Med. Genet. A.<\/i>, <b>185<\/b>, 1468\u20131480 (2021).","DOI":"10.1002\/ajmg.a.62138"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Taii A, Tachikawa M, Ohta Y, Hosoya KI, Terasaki T. Determination of intrinsic creatine transporter (Slc6a8) activity and creatine transport function of leukocytes in rats. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 474\u2013479 (2020).","DOI":"10.1248\/bpb.b19-00807"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mayser W, Schloss P, Betz H. Primary structure and functional expression of a choline transporter expressed in the rat nervous system. <i>FEBS Lett.<\/i>, <b>305<\/b>, 31\u201336 (1992).","DOI":"10.1016\/0014-5793(92)80649-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Guimbal C, Kilimann MWA. Na<sup>+<\/sup>-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. <i>J. Biol. Chem.<\/i>, <b>268<\/b>, 8418\u20138421 (1993).","DOI":"10.1016\/S0021-9258(18)52891-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Schloss P, Mayser W, Betz H. The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>198<\/b>, 637\u2013645 (1994).","DOI":"10.1006\/bbrc.1994.1093"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Colas C, Banci G, Martini R, Ecker GF. Studies of structural determinants of substrate binding in the creatine transporter (CreaT, SLC6A8) using molecular models. <i>Sci. Rep.<\/i>, <b>10<\/b>, 6241 (2020).","DOI":"10.1038\/s41598-020-63189-z"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Dodd JR, Christie DL. Cysteine 144 in the third transmembrane domain of the creatine transporter is located close to a substrate-binding site. <i>J. Biol. Chem.<\/i>, <b>276<\/b>, 46983\u201346988 (2001).","DOI":"10.1074\/jbc.M107137200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Dodd JR, Christie DL. Substituted cysteine accessibility of the third transmembrane domain of the creatine transporter: defining a transport pathway. <i>J. Biol. Chem.<\/i>, <b>280<\/b>, 32649\u201332654 (2005).","DOI":"10.1074\/jbc.M506723200"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ferrada E, Wiedmer T, Wang WA, Frommelt F, Steurer B, Klimek C, Lindinger S, Osthushenrich T, Garofoli A, Brocchetti S, Bradberry S, Huang J, MacNamara A, Scarabottolo L, Ecker GF, Malarstig A, Superti-Furga G. Experimental and computational analysis of newly identified pathogenic mutations in the creatine transporter SLC6A8. <i>J. Mol. Biol.<\/i>, <b>436<\/b>, 168383 (2024).","DOI":"10.1016\/j.jmb.2023.168383"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ndika JD, Lusink V, Beaubrun C, Kanhai W, Martinez-Munoz C, Jakobs C, Salomons GS. Cloning and characterization of the promoter regions from the parent and paralogous creatine transporter genes. <i>Gene<\/i>, <b>533<\/b>, 488\u2013493 (2014).","DOI":"10.1016\/j.gene.2013.10.008"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Bayou N, M\u2019Rad R, Belhaj A, Daoud H, Zemni R, Briault S, Helayem MB, Ben Jemaa L, Chaabouni H. The creatine transporter gene paralogous at 16p11.2 is expressed in human brain. <i>Comp. Funct. Genomics<\/i>, <b>2008<\/b>, 609684 (2008).","DOI":"10.1155\/2008\/609684"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Iyer GS, Krahe R, Goodwin LA, Doggett NA, Siciliano MJ, Funanage VL, Proujansky R. Identification of a testis-expressed creatine transporter gene at 16p11.2 and confirmation of the X-linked locus to Xq28. <i>Genomics<\/i>, <b>34<\/b>, 143\u2013146 (1996).","DOI":"10.1006\/geno.1996.0254"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Barnwell LF, Chaudhuri G, Townsel JG. Cloning and sequencing of a cDNA encoding a novel member of the human brain GABA\/noradrenaline neurotransmitter transporter family. <i>Gene<\/i>, <b>159<\/b>, 287\u2013288 (1995).","DOI":"10.1016\/0378-1119(95)00104-E"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Futagi Y, Narumi K, Furugen A, Kobayashi M, Iseki K. Molecular characterization of the orphan transporter SLC16A9, an extracellular pH- and Na<sup>+<\/sup>-sensitive creatine transporter. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>522<\/b>, 539\u2013544 (2020).","DOI":"10.1016\/j.bbrc.2019.11.137"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yamaguchi A, Mukai Y, Sakuma T, Suganuma Y, Furugen A, Narumi K, Kobayashi M. Molecular characteristic analysis of single-nucleotide polymorphisms in SLC16A9\/hMCT9. <i>Life Sci.<\/i>, <b>334<\/b>, 122205 (2023).","DOI":"10.1016\/j.lfs.2023.122205"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Jomura R, Tanno Y, Akanuma SI, Kubo Y, Tachikawa M, Hosoya KI. Contribution of monocarboxylate transporter 12 to blood supply of creatine on the sinusoidal membrane of the hepatocytes. <i>Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, <b>321<\/b>, G113\u2013G122 (2021).","DOI":"10.1152\/ajpgi.00143.2021"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Abplanalp J, Laczko E, Philp NJ, Neidhardt J, Zuercher J, Braun P, Schorderet DF, Munier FL, Verrey F, Berger W, Camargo SM, Kloeckener-Gruissem B. The cataract and glucosuria associated monocarboxylate transporter MCT12 is a new creatine transporter. <i>Hum. Mol. Genet.<\/i>, <b>22<\/b>, 3218\u20133226 (2013).","DOI":"10.1093\/hmg\/ddt175"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Takahashi M, Kishimoto H, Shirasaka Y, Inoue K. Functional characterization of monocarboxylate transporter 12 (SLC16A12\/MCT12) as a facilitative creatine transporter. <i>Drug Metab. Pharmacokinet.<\/i>, <b>35<\/b>, 281\u2013287 (2020).","DOI":"10.1016\/j.dmpk.2020.01.008"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Fl\u00f6gel S, Strater M, Fischer D, Grundemann D. A creatine efflux transporter in oligodendrocytes. <i>FEBS J.<\/i>, <b>292<\/b>, 1124\u20131140 (2025).","DOI":"10.1111\/febs.17382"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Fezai M, Jemaa M, Fakhri H, Chen H, Elsir B, Pelzl L, Lang F. Down-regulation of the Na<sup>+<\/sup>,Cl<sup>\u2212<\/sup> coupled creatine transporter CreaT (SLC6A8) by glycogen synthase kinase GSK3ss. <i>Cell. Physiol. Biochem.<\/i>, <b>40<\/b>, 1231\u20131238 (2016).","DOI":"10.1159\/000453177"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Shojaiefard M, Hosseinzadeh Z, Bhavsar SK, Lang F. Downregulation of the creatine transporter SLC6A8 by JAK2. <i>J. Membr. Biol.<\/i>, <b>245<\/b>, 157\u2013163 (2012).","DOI":"10.1007\/s00232-012-9424-8"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Fezai M, Warsi J, Lang F. Regulation of the Na<sup>+<\/sup>,Cl<sup>\u2212<\/sup> coupled creatine transporter CreaT (SLC6A8) by the janus kinase JAK3. <i>Neurosignals<\/i>, <b>23<\/b>, 11\u201319 (2015).","DOI":"10.1159\/000442600"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Fezai M, Elvira B, Borras J, Ben-Attia M, Hoseinzadeh Z, Lang F. Negative regulation of the creatine transporter SLC6A8 by SPAK and OSR1. <i>Kidney Blood Press. Res.<\/i>, <b>39<\/b>, 546\u2013554 (2014).","DOI":"10.1159\/000368465"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Li H, Thali RF, Smolak C, Gong F, Alzamora R, Wallimann T, Scholz R, Pastor-Soler NM, Neumann D, Hallows KR. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>299<\/b>, F167\u2013F177 (2010).","DOI":"10.1152\/ajprenal.00162.2010"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Almilaji A, Sopjani M, Elvira B, Borras J, Dermaku-Sopjani M, Munoz C, Warsi J, Lang UE, Lang F. Upregulation of the creatine transporter Slc6A8 by Klotho. <i>Kidney Blood Press. Res.<\/i>, <b>39<\/b>, 516\u2013525 (2014).","DOI":"10.1159\/000368462"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Tachikawa M, Yashiki A, Akanuma SI, Matsukawa H, Ide S, Minami M, Hosoya KI. Astrocytic gamma-aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. <i>Neurochem. Int.<\/i>, <b>113<\/b>, 1\u20137 (2018).","DOI":"10.1016\/j.neuint.2017.11.013"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Ribak CE, Tong WM, Brecha NC. GABA plasma membrane transporters, GAT-1 and GAT-3, display different distributions in the rat hippocampus. <i>J. Comp. Neurol.<\/i>, <b>367<\/b>, 595\u2013606 (1996).","DOI":"10.1002\/(SICI)1096-9861(19960415)367:4<595::AID-CNE9>3.0.CO;2-#"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Minelli A, Barbaresi P, Conti F. Postnatal development of high-affinity plasma membrane GABA transporters GAT-2 and GAT-3 in the rat cerebral cortex. <i>Brain Res. Dev. Brain Res.<\/i>, <b>142<\/b>, 7\u201318 (2003).","DOI":"10.1016\/S0165-3806(03)00007-5"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Jomura R, Tanno Y, Akanuma SI, Kubo Y, Tachikawa M, Hosoya KI. Monocarboxylate transporter 12 as a guanidinoacetate efflux transporter in renal proximal tubular epithelial cells. <i>Biochim. Biophys. Acta Biomembr.<\/i>, <b>1862<\/b>, 183434 (2020).","DOI":"10.1016\/j.bbamem.2020.183434"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Smith KE, Borden LA, Wang CH, Hartig PR, Branchek TA, Weinshank RL. Cloning and expression of a high affinity taurine transporter from rat brain. <i>Mol. Pharmacol.<\/i>, <b>42<\/b>, 563\u2013569 (1992).","DOI":"10.1016\/S0026-895X(25)08972-2"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Tomi M, Tajima A, Tachikawa M, Hosoya K. Function of taurine transporter (Slc6a6\/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. <i>Biochim. Biophys. Acta Biomembr.<\/i>, <b>1778<\/b>, 2138\u20132142 (2008).","DOI":"10.1016\/j.bbamem.2008.04.012"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Yahara T, Tachikawa M, Akanuma S, Kubo Y, Hosoya K. Amino acid residues involved in the substrate specificity of TauT\/SLC6A6 for taurine and gamma-aminobutyric acid. <i>Biol. Pharm. Bull.<\/i>, <b>37<\/b>, 817\u2013825 (2014).","DOI":"10.1248\/bpb.b13-00991"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Tachikawa M, Uchida Y, Ohtsuki S, Terasaki T. Recent Progress in Blood\u2013Brain Barrier and Blood\u2013CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain. <i>Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches<\/i>. (Hammarlund-Udenaes M, de Lange ECM, Thorne RG eds.). Springer New York, New York, NY, pp. 23\u201362 (2014).","DOI":"10.1007\/978-1-4614-9105-7_2"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Uchida Y, Goto R, Usui T, Tachikawa M, Terasaki T. Blood-Arachnoid Barrier as a Dynamic Physiological and Pharmacological Interface Between Cerebrospinal Fluid and Blood. <i>Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches<\/i>. (de Lange ECM, Hammarlund-Udenaes M, Thorne RG eds.). Springer International Publishing, Cham, pp. 93\u2013121 (2022).","DOI":"10.1007\/978-3-030-88773-5_4"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Almeida LS, Verhoeven NM, Roos B, Valongo C, Cardoso ML, Vilarinho L, Salomons GS, Jakobs C. Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. <i>Mol. Genet. Metab.<\/i>, <b>82<\/b>, 214\u2013219 (2004).","DOI":"10.1016\/j.ymgme.2004.05.001"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Wawro AM, Gajera CR, Baker SA, Nirschl JJ, Vogel H, Montine TJ. Creatine transport and pathological changes in creatine transporter deficient mice. <i>J. Inherit. Metab. Dis.<\/i>, <b>44<\/b>, 939\u2013948 (2021).","DOI":"10.1002\/jimd.12358"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, Terasaki T. The blood\u2013brain barrier creatine transporter is a major pathway for supplying creatine to the brain. <i>J. Cereb. Blood Flow Metab.<\/i>, <b>22<\/b>, 1327\u20131335 (2002).","DOI":"10.1097\/01.WCB.0000033966.83623.7D"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Chen HR, Zhang-Brotzge X, Morozov YM, Li Y, Wang S, Zhang HH, Kuan IS, Fugate EM, Mao H, Sun YY, Rakic P, Lindquist DM, DeGrauw T, Kuan CY. Creatine transporter deficiency impairs stress adaptation and brain energetics homeostasis. <i>JCI Insight<\/i>, <b>6<\/b>, e140173 (2021).","DOI":"10.1172\/jci.insight.140173"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Lavina B, Gouveia L, Sun Y, Raschperger E, Rasanen M, Zarb Y, Mochizuki N, Keller A, Lendahl U, Betsholtz C. A molecular atlas of cell types and zonation in the brain vasculature. <i>Nature<\/i>, <b>554<\/b>, 475\u2013480 (2018).","DOI":"10.1038\/nature25739"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Meera P, Uusi-Oukari M, Wallner M, Lipshutz GS. Guanidinoacetate (GAA) is a potent GABA(A) receptor GABA mimetic: implications for neurological disease pathology. <i>J. Neurochem.<\/i>, <b>165<\/b>, 445\u2013454 (2023).","DOI":"10.1111\/jnc.15774"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Marescau B, Deshmukh DR, Kockx M, Possemiers I, Qureshi IA, Wiechert P, De Deyn PP. Guanidino compounds in serum, urine, liver, kidney, and brain of man and some ureotelic animals. <i>Metabolism<\/i>, <b>41<\/b>, 526\u2013532 (1992).","DOI":"10.1016\/0026-0495(92)90213-T"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Tachikawa M, Kasai Y, Yokoyama R, Fujinawa J, Ganapathy V, Terasaki T, Hosoya K. The blood\u2013brain barrier transport and cerebral distribution of guanidinoacetate in rats: involvement of creatine and taurine transporters. <i>J. Neurochem.<\/i>, <b>111<\/b>, 499\u2013509 (2009).","DOI":"10.1111\/j.1471-4159.2009.06332.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Marescau B, De Deyn P, Wiechert P, Van Gorp L, Lowenthal A. Comparative study of guanidino compounds in serum and brain of mouse, rat, rabbit, and man. <i>J. Neurochem.<\/i>, <b>46<\/b>, 717\u2013720 (1986).","DOI":"10.1111\/j.1471-4159.1986.tb13030.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Sora I, Richman J, Santoro G, Wei HB, Wang Y, Vanderah T, Horvath R, Nguyen M, Waite S, Roeske WR, Yamamura HI. The cloning and expression of a human creatine transporter. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>204<\/b>, 419\u2013427 (1994).","DOI":"10.1006\/bbrc.1994.2475"},{"key":"68","unstructured":"68) Nash SR, Giros B, Kingsmore SF, Rochelle JM, Suter ST, Gregor P, Seldin MF, Caron MG. Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. <i>Receptors Channels<\/i>, <b>2<\/b>, 165\u2013174 (1994)."},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, Terasaki T, Hosoya K. The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. <i>J. Neurochem.<\/i>, <b>107<\/b>, 432\u2013442 (2008).","DOI":"10.1111\/j.1471-4159.2008.05641.x"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) De Deyn PP, Vanholder R, Eloot S, Glorieux G. Guanidino compounds as uremic (neuro)toxins. <i>Semin. Dial.<\/i>, <b>22<\/b>, 340\u2013345 (2009).","DOI":"10.1111\/j.1525-139X.2009.00577.x"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) D\u2019Hooge R, Pei YQ, Marescau B, De Deyn PP. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. <i>J. Neurol. Sci.<\/i>, <b>112<\/b>, 96\u2013105 (1992).","DOI":"10.1016\/0022-510X(92)90138-B"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Kasai Y, Akanuma S, Kubo Y, Tachikawa M, Hosoya K. Pharmacokinetics of guanidinosuccinic acid in rat blood and cerebrospinal fluid. <i>Drug Metab. Pharmacokinet.<\/i>, <b>29<\/b>, 97\u2013100 (2014).","DOI":"10.2133\/dmpk.DMPK-13-NT-055"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Tachikawa M, Fujinawa J, Takahashi M, Kasai Y, Fukaya M, Sakai K, Yamazaki M, Tomi M, Watanabe M, Sakimura K, Terasaki T, Hosoya K. Expression and possible role of creatine transporter in the brain and at the blood-cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. <i>J. Neurochem.<\/i>, <b>107<\/b>, 768\u2013778 (2008).","DOI":"10.1111\/j.1471-4159.2008.05652.x"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Conti F, Zuccarello LV, Barbaresi P, Minelli A, Brecha NC, Melone M. Neuronal, glial, and epithelial localization of \u03b3-aminobutyric acid transporter 2, a high-affinity \u03b3-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures. <i>J. Comp. Neurol.<\/i>, <b>409<\/b>, 482\u2013494 (1999).","DOI":"10.1002\/(SICI)1096-9861(19990705)409:3<482::AID-CNE11>3.0.CO;2-O"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Bauer JH, Brooks CS, Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. <i>Am. J. Kidney Dis.<\/i>, <b>2<\/b>, 337\u2013346 (1982).","DOI":"10.1016\/S0272-6386(82)80091-7"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. <i>Annu. Rev. Med.<\/i>, <b>39<\/b>, 465\u2013490 (1988).","DOI":"10.1146\/annurev.me.39.020188.002341"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Sveinbjornsson G, Mikaelsdottir E, Palsson R, Indridason OS, Holm H, Jonasdottir A, Helgason A, Sigurdsson S, Jonasdottir A, Sigurdsson A, Eyjolfsson GI, Sigurdardottir O, Magnusson OT, Kong A, Masson G, Sulem P, Olafsson I, Thorsteinsdottir U, Gudbjartsson DF, Stefansson K. Rare mutations associating with serum creatinine and chronic kidney disease. <i>Hum. Mol. Genet.<\/i>, <b>23<\/b>, 6935\u20136943 (2014).","DOI":"10.1093\/hmg\/ddu399"},{"key":"78","unstructured":"78) K\u00f6ttgen A, Pattaro C, B\u00f6ger CA, <i>et al.<\/i> New loci associated with kidney function and chronic kidney disease. <i>Nat. Genet.<\/i>, <b>42<\/b>, 376\u2013384 (2010)."},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Vallon V, Eraly SA, Rao SR, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK, Rieg T. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>302<\/b>, F1293\u2013F1299 (2012).","DOI":"10.1152\/ajprenal.00013.2012"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Nabeshima S, Reese TS, Landis DM, Brightman MW. Junctions in the meninges and marginal glia. <i>J. Comp. Neurol.<\/i>, <b>164<\/b>, 127\u2013169 (1975).","DOI":"10.1002\/cne.901640202"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Zhang Z, Tachikawa M, Uchida Y, Terasaki T. Drug clearance from cerebrospinal fluid mediated by organic anion transporters 1 (Slc22a6) and 3 (Slc22a8) at arachnoid membrane of rats. <i>Mol. Pharm.<\/i>, <b>15<\/b>, 911\u2013922 (2018).","DOI":"10.1021\/acs.molpharmaceut.7b00852"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Uchida Y, Goto R, Takeuchi H, Luczak M, Usui T, Tachikawa M, Terasaki T. Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT transporters in blood-arachnoid barrier of pig and polarized localizations at CSF- and blood-facing plasma membranes. <i>Drug Metab. Dispos.<\/i>, <b>48<\/b>, 135\u2013145 (2020).","DOI":"10.1124\/dmd.119.089516"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Uchida Y, Takeuchi H, Goto R, Braun C, Fuchs H, Ishiguro N, Takao M, Tano M, Terasaki T. A human blood-arachnoid barrier atlas of transporters, receptors, enzymes, and tight junction and marker proteins: comparison with dog and pig in absolute abundance. <i>J. Neurochem.<\/i>, <b>161<\/b>, 187\u2013208 (2022).","DOI":"10.1111\/jnc.15599"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Pietila R, Del Gaudio F, He L, <i>et al.<\/i> Molecular anatomy of adult mouse leptomeninges. <i>Neuron<\/i>, <b>111<\/b>, 3745\u20133764 e3747 (2023).","DOI":"10.1016\/j.neuron.2023.09.002"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Yaguchi Y, Tachikawa M, Zhang Z, Terasaki T. Organic anion-transporting polypeptide 1a4 (Oatp1a4\/Slco1a4) at the blood-arachnoid barrier is the major pathway of sulforhodamine-101 clearance from cerebrospinal fluid of rats. <i>Mol. Pharm.<\/i>, <b>16<\/b>, 2021\u20132027 (2019).","DOI":"10.1021\/acs.molpharmaceut.9b00005"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) De Deyn PP, D\u2019Hooge R, Van Bogaert PP, Marescau B. Endogenous guanidino compounds as uremic neurotoxins. <i>Kidney Int.<\/i>, <b>78<\/b>, S77\u2013S83 (2001).","DOI":"10.1046\/j.1523-1755.59.s78.51.x"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Zhou Y, Holmseth S, Guo C, Hassel B, Hofner G, Huitfeldt HS, Wanner KT, Danbolt NC. Deletion of the \u03b3-aminobutyric acid transporter 2 (GAT2 and SLC6A13) gene in mice leads to changes in liver and brain taurine contents. <i>J. Biol. Chem.<\/i>, <b>287<\/b>, 35733\u201335746 (2012).","DOI":"10.1074\/jbc.M112.368175"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) deGrauw TJ, Salomons GS, Cecil KM, Chuck G, Newmeyer A, Schapiro MB, Jakobs C. Congenital creatine transporter deficiency. <i>Neuropediatrics<\/i>, <b>33<\/b>, 232\u2013238 (2002).","DOI":"10.1055\/s-2002-36743"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Miyata H, Toyoda Y, Takada T, Hiragi T, Kubota Y, Shigesawa R, Koyama R, Ikegaya Y, Suzuki H. Identification of an exporter that regulates vitamin C supply from blood to the brain. <i>iScience<\/i>, <b>25<\/b>, 103642 (2022).","DOI":"10.1016\/j.isci.2021.103642"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Chung SJ, Ramanathan VK, Brett CM, Giacomini KM. Saturable disposition of taurine in the rat cerebrospinal fluid. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>276<\/b>, 676\u2013682 (1996).","DOI":"10.1016\/S0022-3565(25)12330-6"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Jomura R, Akanuma SI, Kubo Y, Tachikawa M, Hosoya KI. Processing mechanism of guanidinoacetate in choroid plexus epithelial cells: conversion of guanidinoacetate to creatine <i>via<\/i> guanidinoacetate <i>N<\/i>-methyltransferase and monocarboxylate transporter 12-mediated creatine release into the CSF. <i>Fluids Barriers CNS<\/i>, <b>19<\/b>, 42 (2022).","DOI":"10.1186\/s12987-022-00328-w"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) B\u00e9ard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. <i>J. Neurochem.<\/i>, <b>115<\/b>, 297\u2013313 (2010).","DOI":"10.1111\/j.1471-4159.2010.06935.x"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Baroncelli L, Molinaro A, Cacciante F, Alessandri MG, Napoli D, Putignano E, Tola J, Leuzzi V, Cioni G, Pizzorusso T. A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. <i>Hum. Mol. Genet.<\/i>, <b>25<\/b>, 4186\u20134200 (2016).","DOI":"10.1093\/hmg\/ddw252"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Kurosawa Y, Degrauw TJ, Lindquist DM, Blanco VM, Pyne-Geithman GJ, Daikoku T, Chambers JB, Benoit SC, Clark JF. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. <i>J. Clin. Invest.<\/i>, <b>122<\/b>, 2837\u20132846 (2012).","DOI":"10.1172\/JCI59373"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Harris JJ, Attwell D. The energetics of CNS white matter. <i>J. Neurosci.<\/i>, <b>32<\/b>, 356\u2013371 (2012).","DOI":"10.1523\/JNEUROSCI.3430-11.2012"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. <i>Science<\/i>, <b>280<\/b>, 1610\u20131613 (1998).","DOI":"10.1126\/science.280.5369.1610"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Defalco AJ, Davies RK. The synthesis of creatine by the brain of the intact rat. <i>J. Neurochem.<\/i>, <b>7<\/b>, 308\u2013312 (1961).","DOI":"10.1111\/j.1471-4159.1961.tb13518.x"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Philips T, Rothstein JD. Oligodendroglia: metabolic supporters of neurons. <i>J. Clin. Invest.<\/i>, <b>127<\/b>, 3271\u20133280 (2017).","DOI":"10.1172\/JCI90610"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Verouti SN, Lambert D, Mathis D, Pathare G, Escher G, Vogt B, Fuster DG. Solute carrier SLC16A12 is critical for creatine and guanidinoacetate handling in the kidney. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>320<\/b>, F351\u2013F358 (2021).","DOI":"10.1152\/ajprenal.00475.2020"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Dhayat N, Simonin A, Anderegg M, Pathare G, Luscher BP, Deisl C, Albano G, Mordasini D, Hediger MA, Surbek DV, Vogt B, Sass JO, Kloeckener-Gruissem B, Fuster DG. Mutation in the monocarboxylate transporter 12 gene affects guanidinoacetate excretion but does not cause glucosuria. <i>J. Am. Soc. Nephrol.<\/i>, <b>27<\/b>, 1426\u20131436 (2016).","DOI":"10.1681\/ASN.2015040411"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Jomura R, Akanuma SI, Tachikawa M, Hosoya KI. SLC6A and SLC16A family of transporters: Contribution to transport of creatine and creatine precursors in creatine biosynthesis and distribution. <i>Biochim. Biophys. Acta Biomembr.<\/i>, <b>1864<\/b>, 183840 (2022).","DOI":"10.1016\/j.bbamem.2021.183840"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Tachikawa M, Ikeda S, Fujinawa J, Hirose S, Akanuma S, Hosoya K. gamma-Aminobutyric acid transporter 2 mediates the hepatic uptake of guanidinoacetate, the creatine biosynthetic precursor, in rats. <i>PLoS One<\/i>, <b>7<\/b>, e32557 (2012).","DOI":"10.1371\/journal.pone.0032557"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Baker SA, Gajera CR, Wawro AM, Corces MR, Montine TJ. GATM and GAMT synthesize creatine locally throughout the mammalian body and within oligodendrocytes of the brain. <i>Brain Res.<\/i>, <b>1770<\/b>, 147627 (2021).","DOI":"10.1016\/j.brainres.2021.147627"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Peral MJ, Garcia-Delgado M, Calonge ML, Duran JM, De La Horra MC, Wallimann T, Speer O, Ilundain A. Human, rat and chicken small intestinal Na<sup>+<\/sup>-Cl<sup>\u2212<\/sup>-creatine transporter: functional, molecular characterization and localization. <i>J. Physiol.<\/i>, <b>545<\/b>, 133\u2013144 (2002).","DOI":"10.1113\/jphysiol.2002.026377"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Sanders K, Peck D, Bentz Pino G, Studinski Jones A, White A, Gavrilov D, Matern D, Oglesbee D, Schultz M, Tortorelli S, Hall PL. SLC6A8 creatine transporter deficiency can be detected by plasma creatine and creatinine concentrations. <i>Mol. Genet. Metab.<\/i>, <b>142<\/b>, 108455 (2024).","DOI":"10.1016\/j.ymgme.2024.108455"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Stockebrand M, Sasani A, Das D, Hornig S, Hermans-Borgmeyer I, Lake HA, Isbrandt D, Lygate CA, Heerschap A, Neu A, Choe CU. A mouse model of creatine transporter deficiency reveals impaired motor function and muscle energy metabolism. <i>Front. Physiol.<\/i>, <b>9<\/b>, 773 (2018).","DOI":"10.3389\/fphys.2018.00773"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Pertici I, D\u2019Angelo D, Vecellio Reane D, Reconditi M, Morotti I, Putignano E, Napoli D, Rastelli G, Gherardi G, De Mario A, Rizzuto R, Boncompagni S, Baroncelli L, Linari M, Caremani M, Raffaello A. Creatine transporter (SLC6A8) knockout mice exhibit reduced muscle performance, disrupted mitochondrial Ca<sup>2+<\/sup> homeostasis, and severe muscle atrophy. <i>Cell Death Dis.<\/i>, <b>16<\/b>, 99 (2025).","DOI":"10.1038\/s41419-025-07381-x"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Ghirardini E, Calugi F, Sagona G, Di Vetta F, Palma M, Battini R, Cioni G, Pizzorusso T, Baroncelli L. The role of preclinical models in creatine transporter deficiency: neurobiological mechanisms, biomarkers and therapeutic development. <i>Genes<\/i>, <b>12<\/b>, 1123 (2021).","DOI":"10.3390\/genes12081123"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Gechijian LN, Muncipinto G, Rettenmaier TJ, <i>et al.<\/i> Novel corrector for variants of SLC6A8: a therapeutic opportunity for creatine transporter deficiency. <i>ACS Chem. Biol.<\/i>, <b>19<\/b>, 2372\u20132382 (2024).","DOI":"10.1021\/acschembio.4c00571"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) van de Kamp JM, Mancini GM, Salomons GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. <i>J. Inherit. Metab. Dis.<\/i>, <b>37<\/b>, 715\u2013733 (2014).","DOI":"10.1007\/s10545-014-9713-8"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, Vorhees CV. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. <i>PLoS One<\/i>, <b>6<\/b>, e16187 (2011).","DOI":"10.1371\/journal.pone.0016187"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Purpura DP. Dendritic spine \u201cdysgenesis\u201d and mental retardation. <i>Science<\/i>, <b>186<\/b>, 1126\u20131128 (1974).","DOI":"10.1126\/science.186.4169.1126"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Dunbar M, Jaggumantri S, Sargent M, Stockler-Ipsiroglu S, van Karnebeek CD. Treatment of X-linked creatine transporter (SLC6A8) deficiency: systematic review of the literature and three new cases. <i>Mol. Genet. Metab.<\/i>, <b>112<\/b>, 259\u2013274 (2014).","DOI":"10.1016\/j.ymgme.2014.05.011"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Abdulla ZI, Pahlevani B, Lundgren KH, Pennington JL, Udobi KC, Seroogy KB, Skelton MR. Deletion of the creatine transporter (Slc6a8) in dopaminergic neurons leads to hyperactivity in mice. <i>J. Mol. Neurosci.<\/i>, <b>70<\/b>, 102\u2013111 (2020).","DOI":"10.1007\/s12031-019-01405-w"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Udobi KC, Delcimmuto N, Kokenge AN, Abdulla ZI, Perna MK, Skelton MR. Deletion of the creatine transporter gene in neonatal, but not adult, mice leads to cognitive deficits. <i>J. Inherit. Metab. Dis.<\/i>, <b>42<\/b>, 966\u2013974 (2019).","DOI":"10.1002\/jimd.12137"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Lunardi G, Parodi A, Perasso L, Pohvozcheva AV, Scarrone S, Adriano E, Florio T, Gandolfo C, Cupello A, Burov SV, Balestrino M. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. <i>Neuroscience<\/i>, <b>142<\/b>, 991\u2013997 (2006).","DOI":"10.1016\/j.neuroscience.2006.06.058"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) La Du B. Plasma esterase activity and the metabolism of drugs with ester groups. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>179<\/b>, 684\u2013694 (1971).","DOI":"10.1111\/j.1749-6632.1971.tb46944.x"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Fons C, Arias A, Sempere A, Poo P, Pineda M, Mas A, Lopez-Sala A, Garcia-Villoria J, Vilaseca MA, Ozaez L, Lluch M, Artuch R, Campistol J, Ribes A. Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency. <i>Mol. Genet. Metab.<\/i>, <b>99<\/b>, 296\u2013299 (2010).","DOI":"10.1016\/j.ymgme.2009.10.186"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Trotier-Faurion A, Dezard S, Taran F, Valayannopoulos V, de Lonlay P, Mabondzo A. Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency. <i>J. Med. Chem.<\/i>, <b>56<\/b>, 5173\u20135181 (2013).","DOI":"10.1021\/jm400545n"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Giese MW, Lecher CS. Non-enzymatic cyclization of creatine ethyl ester to creatinine. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>388<\/b>, 252\u2013255 (2009).","DOI":"10.1016\/j.bbrc.2009.07.151"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Trotier-Faurion A, Passirani C, Bejaud J, Dezard S, Valayannopoulos V, Taran F, de Lonlay P, Benoit JP, Mabondzo A. Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. <i>Nanomedicine<\/i>, <b>10<\/b>, 185\u2013191 (2015).","DOI":"10.2217\/nnm.13.205"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Ullio-Gamboa G, Udobi KC, Dezard S, Perna MK, Miles KN, Costa N, Taran F, Pruvost A, Benoit JP, Skelton MR, Lonlay P, Mabondzo A. Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency. <i>Nanomedicine<\/i>, <b>14<\/b>, 1579\u20131593 (2019).","DOI":"10.2217\/nnm-2019-0059"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Adriano E, Gulino M, Arkel M, Salis A, Damonte G, Liessi N, Millo E, Garbati P, Balestrino M. Di-acetyl creatine ethyl ester, a new creatine derivative for the possible treatment of creatine transporter deficiency. <i>Neurosci. Lett.<\/i>, <b>665<\/b>, 217\u2013223 (2018).","DOI":"10.1016\/j.neulet.2017.12.020"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Garbati P, Adriano E, Salis A, Ravera S, Damonte G, Millo E, Balestrino M. Effects of amide creatine derivatives in brain hippocampal slices, and their possible usefulness for curing creatine transporter deficiency. <i>Neurochem. Res.<\/i>, <b>39<\/b>, 37\u201345 (2014).","DOI":"10.1007\/s11064-013-1188-8"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Burov S, Leko M, Dorosh M, Dobrodumov A, Veselkina O. Creatinyl amino acids: new hybrid compounds with neuroprotective activity. <i>J. Pept. Sci.<\/i>, <b>17<\/b>, 620\u2013626 (2011).","DOI":"10.1002\/psc.1379"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Uemura T, Ito S, Masuda T, Shimbo H, Goto T, Osaka H, Wada T, Couraud PO, Ohtsuki S. Cyclocreatine transport by SLC6A8, the creatine transporter, in HEK293 cells, a human blood\u2013brain barrier model cell, and CCDSs patient-derived fibroblasts. <i>Pharm. Res.<\/i>, <b>37<\/b>, 61 (2020).","DOI":"10.1007\/s11095-020-2779-0"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) da Silva RP. The dietary supplement creatyl-L-leucine does not bioaccumulate in muscle, brain or plasma and is not a significant bioavailable source of creatine. <i>Nutrients<\/i>, <b>14<\/b>, 701 (2022).","DOI":"10.3390\/nu14030701"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Uemura T, Ito S, Ohta Y, Tachikawa M, Wada T, Terasaki T, Ohtsuki S. Abnormal <i>N<\/i>-glycosylation of a novel missense creatine transporter mutant, G561R, associated with cerebral creatine deficiency syndromes alters transporter activity and localization. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 49\u201355 (2017).","DOI":"10.1248\/bpb.b16-00582"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) El-Kasaby A, Kasture A, Koban F, Hotka M, Asjad HMM, Kubista H, Freissmuth M, Sucic S. Rescue by 4-phenylbutyrate of several misfolded creatine transporter-1 variants linked to the creatine transporter deficiency syndrome. <i>Neuropharmacology<\/i>, <b>161<\/b>, 107572 (2019).","DOI":"10.1016\/j.neuropharm.2019.03.015"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Nakamura S, Osaka H, Muramatsu SI, Takino N, Ito M, Aoki S, Jimbo EF, Shimazaki K, Onaka T, Ohtsuki S, Terasaki T, Yamagata T. Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. <i>Mol. Genet. Metab. Rep.<\/i>, <b>10<\/b>, 67\u201374 (2017).","DOI":"10.1016\/j.ymgmr.2016.12.008"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Nakamura S, Muramatsu SI, Takino N, Ito M, Jimbo EF, Shimazaki K, Onaka T, Ohtsuki S, Terasaki T, Yamagata T, Osaka H. Gene therapy for Glut1-deficient mouse using an adeno-associated virus vector with the human intrinsic GLUT1 promoter. <i>J. Gene Med.<\/i>, <b>20<\/b>, e3013 (2018).","DOI":"10.1002\/jgm.3013"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) Fernandes-Pires G, Azevedo MD, Lanzillo M, Roux-Petronelli C, Binz PA, Cudalbu C, Sandi C, Tenenbaum L, Braissant O. Rescue of myocytes and locomotion through AAV2\/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency. <i>Mol. Ther. Methods Clin. Dev.<\/i>, <b>32<\/b>, 101251 (2024).","DOI":"10.1016\/j.omtm.2024.101251"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Mabondzo A, Harati R, Broca-Brisson L, Guyot AC, Costa N, Cacciante F, Putignano E, Baroncelli L, Skelton MR, Saab C, Martini E, Benech H, Joudinaud T, Gaillard JC, Armengaud J, Hamoudi R. Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency. <i>Front. Mol. Neurosci.<\/i>, <b>16<\/b>, 1118707 (2023).","DOI":"10.3389\/fnmol.2023.1118707"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Broca-Brisson L, Harati R, Disdier C, Mozner O, Gaston-Breton R, Maiza A, Costa N, Guyot AC, Sarkadi B, Apati A, Skelton MR, Madrange L, Yates F, Armengaud J, Hamoudi R, Mabondzo A. Deciphering neuronal deficit and protein profile changes in human brain organoids from patients with creatine transporter deficiency. <i>eLife<\/i>, <b>12<\/b>, RP88459 (2023).","DOI":"10.7554\/eLife.88459.3"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135) Rahhal S, Farmer C, Thurm A, Wassif CA, Cawley NX, Perreault J, Dang Do A, Bianconi S, Hannah-Shmouni F, Guthrie W, Cubit LS, Miller JS, Sutton VR, Koeberl D, Porter FD. Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency. <i>Mol. Genet. Metab. Rep.<\/i>, <b>37<\/b>, 101001 (2023).","DOI":"10.1016\/j.ymgmr.2023.101001"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136) Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood\u2013brain barrier transporters and receptors. <i>J. Neurochem.<\/i>, <b>117<\/b>, 333\u2013345 (2011).","DOI":"10.1111\/j.1471-4159.2011.07208.x"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137) Gyimesi G, Hediger MA. Transporter-mediated drug delivery. <i>Molecules<\/i>, <b>28<\/b>, 1151 (2023).","DOI":"10.3390\/molecules28031151"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138) Omori K, Tachikawa M, Hirose S, Taii A, Akanuma SI, Hosoya KI, Terasaki T. Developmental changes in transporter and receptor protein expression levels at the rat blood\u2013brain barrier based on quantitative targeted absolute proteomics. <i>Drug Metab. Pharmacokinet.<\/i>, <b>35<\/b>, 117\u2013123 (2020).","DOI":"10.1016\/j.dmpk.2019.09.003"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139) Dai W, Vinnakota S, Qian X, Kunze DL, Sarkar HK. Molecular characterization of the human CRT-1 creatine transporter expressed in Xenopus oocytes. <i>Arch. Biochem. Biophys.<\/i>, <b>361<\/b>, 75\u201384 (1999).","DOI":"10.1006\/abbi.1998.0959"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140) Dodd JR, Zheng T, Christie DL. Creatine accumulation and exchange by HEK293 cells stably expressing high levels of a creatine transporter. <i>Biochim. Biophys. Acta, Gen. Subj.<\/i>, <b>1472<\/b>, 128\u2013136 (1999).","DOI":"10.1016\/S0304-4165(99)00113-0"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141) Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. <i>Pharm. Res.<\/i>, <b>21<\/b>, 976\u2013981 (2004).","DOI":"10.1023\/B:PHAM.0000029286.45788.ad"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142) Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. <i>Clin. Pharmacol. Ther.<\/i>, <b>89<\/b>, 81\u201388 (2011).","DOI":"10.1038\/clpt.2010.232"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143) Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, Murray BP, Bannister R, Cihlar T, Huang Y, Ray AS. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. <i>Kidney Int.<\/i>, <b>86<\/b>, 350\u2013357 (2014).","DOI":"10.1038\/ki.2014.66"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144) Omote S, Matsuoka N, Arakawa H, Nakanishi T, Tamai I. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. <i>Sci. Rep.<\/i>, <b>8<\/b>, 9237 (2018).","DOI":"10.1038\/s41598-018-27672-y"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145) Duran-Trio L, Fernandes-Pires G, Simicic D, Grosse J, Roux-Petronelli C, Bruce SJ, Binz PA, Sandi C, Cudalbu C, Braissant O. A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism. <i>Sci. Rep.<\/i>, <b>11<\/b>, 1636 (2021).","DOI":"10.1038\/s41598-020-80824-x"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146) Baroncelli L, Alessandri MG, Tola J, Putignano E, Migliore M, Amendola E, Gross C, Leuzzi V, Cioni G, Pizzorusso T. A novel mouse model of creatine transporter deficiency. <i>F1000Res.<\/i>, <b>3<\/b>, 228 (2014).","DOI":"10.12688\/f1000research.5369.1"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147) Udobi KC, Kokenge AN, Hautman ER, Ullio G, Coene J, Williams MT, Vorhees CV, Mabondzo A, Skelton MR. Cognitive deficits and increases in creatine precursors in a brain-specific knockout of the creatine transporter gene Slc6a8. <i>Genes Brain Behav.<\/i>, <b>17<\/b>, e12461 (2018).","DOI":"10.1111\/gbb.12461"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/4\/49_b25-00796\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:11:20Z","timestamp":1775275880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/4\/49_b25-00796\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00796","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"b25-00796"}}